CRDL Company Profile and Key Details

CRDL has shown mixed momentum, gaining 5.21% over the past week and -1.94% over the past quarter, though year-to-date performance is up 5.89%. Short-term trend indicators are mixed aligned (SMA20 5.28%, SMA50 6.29%, SMA200 -5.61%). The stock’s 14-day RSI is 58.47 (neutral), while the ATR of 0.06 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -32.7% below its high and over 38.8% above its low. Average 10-day trading volume of 1.96 million shares is significantly above the 3-month average of 878.08 thousand, indicating heightened recent market interest.

Cardiol Therapeutics Inc. has 116.82 million shares outstanding. The public float is 92.07 million shares, elevated short interest at 2.01% of float. This equals 2.25 million shares. The short ratio is 2.54 days. Institutional investors hold 25.3% of the float. Insiders own 2.38%.

Cardiol Therapeutics Inc. generated EPS of -$0.30 over the past year. Five-year average earnings growth is 1.3%. Wall Street analysts project EPS growth of 21.9% annually over the next five years. The latest quarter delivered EPS of -$0.04. The next quarter is forecast at -$0.08. Next year's EPS is expected at $13.65. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 4 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $9.00 to $8.00. The high target offers 320.56% upside. The low target suggests 273.83% downside. The mean target is $8.75. This offers 308.88% upside. Cardiol Therapeutics Inc. earnings surprise history is a mixed track record. The quarter that ended August 13, 2026, missed forecasts by -55.56%. The prior quarter beat by -55.56%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in November 13, 2025.

Cardiol Therapeutics Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.18. This means the shares are trading above this model’s fair value.

Cardiol Therapeutics Inc. (NASDAQ:CRDL) closed at $2.14 USD, gaining $0.14 (7.00%) from the previous close of $2.00. The stock is currently mid-range between its 52-week high and low $0.88 and $2.27. With a market capitalization of about $246.68 million, Cardiol Therapeutics Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.47). Key stats such as the average daily volume over the past year has been around 872.82 thousand shares, trading with heavier-than-usual volume. Headquartered in Oakville, ON, Cardiol Therapeutics Inc. operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO David G. Elsley, the company employs approximately 18 people and listed since January 15, 2019. Cardiol Therapeutics Inc. is a clinical-stage life sciences firm dedicated to discovering and advancing anti-fibrotic and anti-inflammatory therapies for cardiovascular disease (CVD).

Cardiol Therapeutics Inc. trades at a P/E ratio of -8.55, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 14.83 reflecting a rich premium to book value. The P/FCF stands at -14.82, also below market averages. Compared to sector medians, Cardiol Therapeutics Inc. P/S is trading at a discount to the sector, and the P/B is far lower than peers, underscoring the brand and earnings power premium investors assign to the stock.

Our AI price prediction model suggests that Cardiol Therapeutics Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 18.22%, with price expected at $2.53 by September 09, 2026, within a range of $2.44 to $2.63 3-Month Outlook: Projected fall of -14.95%, reaching $1.82 by November 24, 2026, with a range of $1.74 to $1.88. 1-Year Outlook: Projected gain of 977.57%, with price at $23.06 by August 26, 2027, within a range of $17.61 to $30.21.

Cardiol Therapeutics Inc. (NASDAQ:CRDL) shares are flat 5.89% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Cardiol Therapeutics Inc. trading at a premium to the broader market with a P/E of -8.55. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $8.36, suggesting 290.65% upside. Our AI forecast model points to short-term strength (18.22% over two weeks), a medium-term fall (-14.95% over three months), and a longer-term gain (977.57% over one year), with expected trading ranges indicating moderate volatility.